Introduction
Voltage-gated sodium (Na v ) channels are critical for the initiation and propagation of action potentials in electrically excitable cells (Hodgkin and Huxley, 1952; Bezanilla, 2006; Catterall, 2012) . In mammals, there are nine Na v channel subtypes that can have broad or highly localized tissue expression distribution, which enables them to serve distinct physiological functions such as neuronal electrical signalling, neurotransmitter release, cardiac and skeletal muscle contraction and non-excitatory roles (Cummins et al., 2007; Catterall, 2012; Black and Waxman, 2013) . The importance of Na v channels in these physiological processes is highlighted by numerous reports of human Na v genetic channelopathies associated with pain, epilepsy, autism, cardiac arrhythmias and skeletal muscle myotonias (Catterall, 2012; Eijkelkamp et al., 2012; Bennett and Woods, 2014; Krumm et al., 2014; Miller et al., 2014; Moreau et al., 2014; Waxman et al., 2014) . Because of this association, pharmacological modulation of sodium channel function has been a primary mode of clinical intervention to treat many of these disorders. Therefore, there is considerable interest in developing Na v subtype-selective drug candidates (England and de Groot, 2009 ). Much of the recent focus and success has been in the identification and development of selective inhibitors of Na v 1.8, Na v 1.3 and Na v 1.7 sodium channel subtypes (Jarvis et al., 2007; Kort et al., 2008; Zhang et al., 2010; McCormack et al., 2013; Lee et al., 2014; Sun et al., 2014; Ahuja et al., 2015; Bagal et al., 2015; Payne et al., 2015; Alexandrou et al., 2016) . However, recent reports that human Na v 1.1, Na v 1.2, Na v 1.3 and Na v 1.6 channel loss of function mutations can lead to seizure disorders and some forms of autism have increased interest in potentially developing drug candidates that can enhance Na v channel activity (Jensen et al., 2014; Blanchard et al., 2015; Crestey et al., 2015; Lamar et al., 2017; Wolff et al., 2017) Development of selective small molecule Na v channel inhibitors was recently aided by the identification and characterization of a novel pharmacological interaction region on the homologous domain 4 voltage sensor of the channel (McCormack et al., 2013; Ahuja et al., 2015) . This region is distinct from the more well characterized local anaesthetic binding site located within the pore of the channel (Ragsdale et al., 1994; Ragsdale et al., 1996; Fozzard et al., 2011; Panigel and Cook, 2011) , which is believed to be the site of interaction for many of the clinically used non-selective Na v channel modulators. The homologous domain 4 voltage sensor is also the site of interaction of venom peptide toxins from scorpions, sea anemones and wasps that enhance conduction of Na v channels via a slowing of the inactivation process (Leipold et al., 2004; Gilchrist et al., 2014) . Many of these toxins exhibit Na v channel subtype selectivity which suggests that the homologous domain 4 voltage sensor may be an attractive target for the development of selective low MW enhancers of Na v channel conduction. In the current study, we describe the characterization of a novel compound PF-06526290 identified during a screen of compounds that had some structural relationship to the selective aryl sulfonamide class of inhibitors previously shown to interact with the homologous domain 4 voltage sensor (McCormack et al., 2013; Ahuja et al., 2015) . This novel Na v channel modulator exhibits both enhancement and inhibition of Na v channels function and that the divergent functions may result from distinct interactions with the channel that may include the homologous domain 4 voltage sensor region.
Methods

Cell line generation/isolation
Human Na v 1.3, Na v 1.7, Na v 1.3 M123-S1510Y/R1511W/ E1559D and Na v 1.7 M123-Y1537S/W1538R/D1586E channels were stably expressed in HEK293 cells. K v 1.1/K v 1.2 (heteromultimer) channels were stably expressed in CHO cells. Methods of stable cell line generation were as described in McCormack et al. (2013) . Mouse dorsal root ganglion (DRG) neurons were isolated as described by Gandini et al. (2014) .
Electrophysiology
Studies were performed using conventional or automated whole-cell patch clamp electrophysiology. Extracellular recording solution contained 138 mM NaCl, 2 mM CaCl 2 , 5.4 mM KCl, 1 mM MgCl 2 , 5 mM glucose and 10 mM HEPES, pH 7.4 with NaOH. For DRG neuron voltage-clamp recordings sodium concentration was reduced to 40 mM (i.e. 98 mM choline chloride substituted for NaCl) while remaining constituents were unchanged. Internal (intracellular) recording solutions for sodium current contained 110 mM CsF, 35 mM CsCl, 5 mM NaCl, 5 mM EGTA and 10 mM HEPES pH 7.4 with CsOH (KF replaced CsF for potassium current recording). Recordings were performed at room temperature using AXOPATCH 200B amplifier and pCLAMP software or PatchXpress 7000 (Molecular Devices). Peak current amplitudes ranging 2-10 nA were used for characterization of our compounds. Voltage errors were minimized using 80% series resistance compensation.
Test agents were made up as 10 mM DMSO stock solutions and diluted in extracellular solution to attain final concentrations desired. The final concentration of DMSO (<0.3%) had no effect on recorded current properties. Toxin stock solutions were made at 100 μM in the extracellular recording solution and stored at À20°C. Before use, stock solution was diluted in recording solution containing 0.1% of bovine serum albumin. All reagents were applied to cells via a parallel pipe perfusion system (Castle et al., 2003) . Experimental protocols and test agent were not randomized because, for the most part, only one compound and one experimental protocol was evaluated on an individual cell. All compound testing followed a control measurement period.
For current-clamp recordings, pipette solution contained the following: 140 mM K-Aspartate, 10 mM KCl, 8 mM NaCl, 20 μM EGTA, 10 mM HEPES, 1 mM MgCl 2 , 2 mM Mg-ATP and 0.4 mM Na-GTP, pH 7.4 with KOH; and the bath solution contained 138 mM NaCl, 2 mM CaCl 2 , 5.4 mM KCl, 1 mM MgCl 2 , 5 mM glucose and 10 mM HEPES, pH 7.4 with NaOH. Action potential current threshold was determined by the first action potential elicited by a series of depolarizing current injections (30 ms) from 10 pA with 10 pA increments. Action potential frequency was determined by quantifying the number of action potentials elicited in response to 500 ms 150 pA current injections.
Data and statistical analysis
Data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Electrophysiological data were analysed using Clampfit 10.3 (Molecular Devices) and GraphPad Prism 6.0 (GraphPad Software, Inc., San Diego, CA, USA). Statistical analysis of data was performed using Student's t-test or ANOVA where appropriate. Statistical significance was set at P < 0.05. All data are presented as individual data points and/or mean values ± SEM.
Materials
PF-06526290 was synthesized by the medicinal chemistry group at Pfizer. Scorpion α-like toxin Lqh III was purchased from Latoxan, France, and tetrodotoxin (TTX) was bought from Sigma Aldrich.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017) .
Results
PF-06526290 slows Na v channel inactivation
The compound, PF-06526290 ( Figure 1A ), was identified during a screen for novel Na v 1.3 channel inhibitors. In contrast to inhibition, the most noticeable effect of PF-06526290 was a slowing of the rate of Na v 1.3 current inactivation. Figure 1 B shows that depolarization from À120 to 0 mV in the presence of 10 μM PF-06526290 resulted in activation of Na v 1.3 currents that exhibited greatly slowed inactivation compared to non-treated controls [τ inact (control) = 0.82 ± 0.04 ms, n = 15 vs. τ inact (PF-06526290) = 96 ± 9 ms, n = 6]. Figure 1C shows that 10 μM PF-06526290 produces a similar slowing of inactivation of human Na v 1.7 currents. The concentration dependence of slowing of inactivation ( Figure 1D ) was determined by normalizing the current amplitude 5 ms after start of depolarizing voltage step in the presence and absence of PF-06526290 to peak sodium current amplitude. The EC 50 s are 1.1 ± 0.1 μM (n = 6) for Na v 1.3 and 0.27 ± 0.08 μM (n = 5) for Na v 1.7 channels. Maximal slowing of Na v 1.7 inactivation with 10 μM PF-06526290 occurred within 2 min, and Magnitude of PF-06526290-induced slowing of inactivation was calculated by normalizing sodium current amplitude 5 ms after peak-to-peak amplitude; EC 50 0.27 ± 0.08 μM (n = 5) for Na v 1.7 and 1.1 ± 0.1 μM (n = 6) for Na v 1.3 channels. Data values for Na v 1.7 channels derived from 21 cells from nine separate cell preparations. Data values for Na v 1.3 channels derived from 20 cells from eight separate cell preparations. more than 80% of this effect could be reversed by washout for 10 min (Figure 2A) . We investigated the possibility that β1 and β2 auxiliary subunits coexpressed with Na v 1.7 channels might modulate slowing of inactivation produced by PF-06526290. However, no effect was observed ( Figure 2B, C) . Figure 3A shows that slowing of inactivation by PF-06526290 was observed for all Na v channels subtypes evaluated, although the magnitude of effect at 10 μM was noticeably less for human Na v 1.4 and Na v 1.8 channels. The quantification of inactivation slowing (I 5ms /I Peak ratio) for each of the channel subtypes is summarized in the plot in Figure 3B . Figure 4A , B shows the peak current amplitude versus stimulating voltage relationship for Na v 1.3 and Na v 1.7 channels in the absence and presence of 10 μM PF-06526290. For both channel subtypes, there was a PF-06526290-associated increase in peak current amplitude at voltages near the activation threshold. Figure 4C , D shows that PF-06526290 produced a hyperpolarizing shift in voltage dependence of activation for both Na v 1.3 and Na v 1.7 channels and a larger depolarizing shift in voltage dependence of inactivation. At sub-maximal effective concentrations of PF-06526290, the voltage dependence of inactivation of Na v 1.7 channels exhibited a double Boltzmann voltage relationship, which could be fit with two midpoint inactivation potentials and slopes equal to either control (À70 mV) or 10 μM compound (À32 mV). However, the relative proportion of the depolarized midpoint potential component (i.e. À32 mV) increased with higher PF-06526290 concentrations ( Figure 4E ) suggesting that this reflects the voltage dependence of inactivation of modified channels.
Multiple modes of modulation of Na v channels by PF-06526290
The ability of PF-06526290 to slow current inactivation when activated from À120 mV suggests that the compound interacts with the channel in a closed resting state. Although PF-06526290 slows Na v channel inactivation, it does eventually reach completion. This allowed for the evaluation of compound interaction with inactivated Na v 1.3 and Na v 1.7 channels. Figure 5A , B shows that after a 5 s conditioning voltage step to 0 mV (channels are completely inactivated for >4.5 s) followed by a 50 ms rest at À120 mV to allow Figure 2 (A) Time course of 10 μM PF-06526290 slowing of inactivation of hNa v 1.7 channels and washout. Time course of Na v 1.7 5 ms/peak current ratio was normalized to the maximal response in each experimental run just prior to compound washout. Data shown are mean ± SEM for five to six separate experiments. (B) Sodium channel auxiliary subunits β1 and β2 have no effects on PF-06526290 (PF-290) induced slowing of inactivation or inhibition. Representative current traces of Na v 1.7 + β1/β2 subunits with and without 10 μM PF-06526290 induced by a two-pulse test protocol as shown in Figure 1 . (C) Co-expression of β1/β2 subunits with Na v 1.7 had no effect on PF-06526290 induced slowing of inactivation (I 5ms /I peak ) compared to Na v 1.7 α subunit only expressing cells. Individual data for Na v 1.7 β1/β2 from seven separate cells from two different cell preparations. Individual data for Na v 1.7 from nine separate cells from three different cell preparations. *P < 0.05, significantly different as indicated; N.S., not significant; ANOVA. unmodified channels to recover from inactivation, Na v 1.3 but not Na v 1.7 currents elicited by the Pulse 2 voltage step to 0 mV were reduced by 10 μM PF-06526290. The concentration dependence of inhibition is shown in Figure 5C with the IC 50 s being 5.1 ± 2.5 μM (n = 6) for Na v 1.3 and >30 μM (n = 6) for Na v 1.7 channels. The inhibitory effect of PF-06526290 was also observed for Na v 1.1, Na v 1.6 and Na v 1.5 channels but was absent or less evident for Na v 1.8, Na v 1.4 and Na v 1.2 channels ( Figure 5D ).
PF-06526290 is functionally displaced from Na v channel during inactivation process
An intriguing observation is that despite the absence of inhibition of Na v 1.7 channels by PF-06526290, currents elicited after a 5 s depolarization to 0 mV lacked the slowed inactivation seen prior to this voltage step ( Figure 5A ). Although not as obvious, a similar effect was observed with Na v 1.3 channels. If the non-inhibited component of Pulse 2 Na v 1.3 current in the presence of PF-06526290 is scaled to control, little or no slowed inactivation is evident ( Figure 5A scaled trace). What is the explanation for this finding? One possibility is that binding of PF-06526290 and the process of inactivation are mutually exclusive, and the observed slowed inactivation reflects competition between the two processes. If this was the case, then the time course of modified inactivation would be expected to be dependent on PF-06526290 concentration. Figure 6A -C shows that time course of the slow component of inactivation is concentration independent, although the proportion of current that inactivates slowly is dependent on concentration. An alternative explanation for the concentration-independent slowing of inactivation is that PF-06526290 prevents a fast inactivation process to expose a slower inactivation process upon which the compound has no effect. Furthermore, the channel conformation associated with this slow inactivated state has a much lower affinity for PF-06526290, so it dissociates from the channel and can only rebind when the channel returns to a resting closed state. Evidence supporting this hypothesis is shown in Figure 6D -F. Figure 6D shows slowed inactivation of Na v 1.7 current induced by 1 μM PF-06526290 following a 20 ms voltage step from À120 to 0 mV. Figure 6E shows that when a 500 ms conditioning voltage step to 0 mV to inactivate channels is applied in the presence of 1 μM PF-06526290, followed by a 30 ms resting period at À120 mV to allow a majority of unmodified channels to recover from inactivation, currents elicited by a 20 ms voltage step to 0 mV exhibited little or no slowed inactivation. However, when the rest period at À120 mV was extended to 400 ms, 30% of the current inactivated with slow kinetics, and when the resting period at À120 mV was further extended to 2 s, the current profile was similar to that seen in the absence of a conditioning voltage step to induce inactivation ( Figure 6D , E). The rate of redevelopment of slowed inactivation increased with PF-06526290 concentration ( Figure 6F ).
Figure 3
(A) Effect of 10 μM PF-06526290 on current amplitude and rate of inactivation of human Na v 1.1, Na v 1.2, Na v 1.4, Na v 1.5, Na v 1.6 and Na v 1.8 sodium currents elicited by Pulse 1 of the protocol illustrated in Figure 1B. (B) For each sodium channel subtype, I 5ms /I Peak ratio before (left-hand data set) and after (right-hand data set) application of 10 μM PF-06526290 is shown. Each pair of data points for individual channel subtypes represent a separate cell recording. Data points are from 5 to 14 separate cells from two to three different cell preparations for each channel type except Na v 1.5 which is from four separate cells from one cell preparation. *P < 0.05, significantly different as indicated; t-test.
Furthermore, the time course for the redevelopment of slowed inactivation at the highest concentration tested (10 μM) was similar to the time course of the slow component of recovery from inactivation ( Figure 6F ).
Slowing of inactivation and inhibition by PF-06526290 result from distinct interactions with the channel
While the explanation in the previous section can mechanistically account for the loss of slowed inactivation of both Na v 1.7 and Na v 1.3 channels following sustained depolarization in the presence of PF-06526290, it does not account for the subtype-selective inhibition of Na v 1.3 channels, which appears to be dependent on prolonged depolarization. The structure of PF-06526290 includes a thiazole motif which is also present in the aryl sulfonamide class of subtypeselective inhibitors that have been shown to interact with the domain 4 voltage sensor domain (D4 VSD) of the sodium channel (McCormack et al., 2013; Ahuja et al., 2015; Alexandrou et al., 2016) . To evaluate if the functional effects of PF-06526290 resulted from an interaction with this region of the sodium channel, we examined the effect of previously characterized mutant forms of Na v 1.3 and Na v 1.7 channels where a 3 amino residue motif termed M123 swapped residues found in Na v 1.3 with those present in Na v 1.7 channels (Na v 1.3 M123 -S1510Y/R1511W/E1559D) or vice versa for Na v 1.7 (Na v 1.7 M123 -Y1537S/W1538R/ D1586E) (McCormack et al., 2013) . Figure 7A compares the concentration dependence of PF-06526290-mediated inhibition of Na v 1.3, Na v 1.7 and the respective Na v 1.3/Na v 1.7 M123 domain 4 voltage sensor mutants. The potency of inhibition of Na v 1.3 M123 was decreased eightfold relative to Na v 1.3 channels while inhibition of Na v 1.7 M123 was
Figure 4
Effect of PF-06526290 on voltage dependence of activation and inactivation of Na v 1.3 and Na v 1.7 channels. (A, B) Normalized peak current amplitude versus stimulating voltage, for hNa v 1.3 and hNa v 1.7 channels in the absence and presence of 10 μM PF-06526290. Control currents were normalized to maximum current amplitude in the absence of PF-06526290, while compound effect on current amplitude for each cell was normalized to the maximal control current for that cell. Data shown are mean ± SEM for four to five separate cell recordings. (C, D) Voltage dependence of activation and inactivation of Na v 1.3 and Na v 1.7 channels in the absence and presence of 10 μM PF-06526290. Normalized conductance in the presence of PF-06526290 was measured 5 ms after peak current. [hNa v 1.3: Activation V 1/2 : À12 ± 1, k: 7 ± 1.0 (n = 5); inactivation V 1/2 : À52 ± 1, k: 6 ± 1 (n = 5); With 10 μM PF-06526290: Activation V 1/2 : À19 ± 1, k: 6 ± 1 (n = 5); Inactivation V 1/2 : À37 ± 2, k: 13 ± 2 (n = 5). hNa v 1.7: Activation V 1/2 : À20 ± 1, k: 6 ± 1 (n = 4); Inactivation V 1/2 : À70 ± 0.6, k: 6 ± 0.5 (n = 5); With 10 μM PF-06526290: Activation V 1/2 : À32 ± 1, k: 6 ± 1 (n = 3); Inactivation V 1/2 : À32 ± 1, k: 6 ± 1) (n = 6)]. Data generated from two separate cell preparations. (E) Voltage dependence of inactivation of Na v 1.7 in the presence of 0.1, 1 and 10 μM PF-06526290 (n = 5-6 cells from two separate cell preparations). Each data set was fitted to a double Boltzmann Equation where each of the V 1/2 and slope of inactivation parameters were fixed to either the control or 10 μM PF-06526290 values shown in (D). However, the relative proportion of current with either the À70 or À32 mV V 1/2 was adjusted to give the best fit for each concentration of PF-06526290 tested.
Multiple modes of Na v channel modulation by PF-06526290 enhanced sevenfold relative to Na v 1.7 channels, suggesting that the D4 VSD region may be involved this action. In contrast, Figure 7B shows that the mutation of Na v 1.3 or Na v 1.7 M123 residues had no obvious effect on the potency or magnitude of slowing of inactivation of either Na v 1.3 or Na v 1.7 channels. The absence of a change in magnitude or potency for slowing of inactivation with either Na v 1.3 M123 or Na v 1.7 M123 mutants may be explained by the fact that both Na v 1.3 and Na v 1.7 channels are sensitive to the inactivation slowing actions of PF-06526290. Therefore, swapping Na v 1.3 for Na v 1.7 residues or vice versa in the Na v 1.3 M123 and Na v 1.7 M123 mutants may have resulted in channels similarly sensitive to slowing of inactivation by PF-06526290.
The slowing of inactivation by PF-06526290 resembled the actions of scorpion venom α toxins and sea anemone toxins which have been reported to bind to the Na v channel domain 4 voltage sensor (Leipold et al., 2004; Gilchrist et al., 2014) . Furthermore, at least one of the residues in the M123 motif important for inhibition by PF-06526290 is important for α-scorpion toxin action (Leipold et al., 2004; Gilchrist et al., 2014) . Therefore, we evaluated if PF-06526290 could modulate the ability of α-scorpion toxin to slow Na v 1.7 channel inactivation. The effect of the
Figure 5
PF-06526290 produces subtype-selective inhibition of Na v channels following prolonged depolarization. (A) Comparison of PF-06526290 effects on Na v 1.3 and Na v 1.7 current traces elicited by protocol shown in (B). Whereas slowing of inactivation by 10 μM PF-06526290 is observed for both channel subtypes with Pulse 1 only inhibition of Na v 1.3 current was observed with Pulse 2. Furthermore, neither Na v 1.7 nor Na v 1.3 current traces elicited by Pulse 2 exhibited the slowing of inactivation observed with Pulse 1 (for Na v 1.3, the blue trace reflects the uninhibited component scaled to control). (C) Concentration dependence of human Na v 1.3 and Na v 1.7 inhibition by PF-06526290 [IC 50 5 ± 2 μM (n = 6 cells from two cell preparations) for Na v 1.3 channels and > 30 μM (n = 6 cells from two cell preparations) for Na v 1.7 channels]. (D) Inhibition effect of PF-06526290 on different Na v channel subtypes tested. For each sodium channel subtype, data before (left-hand data set) and after (right-hand data set) application of 10 μM PF-06526290 are shown. *P < 0.05; significantly different as indicated; Student's t-test. α-like scorpion toxin, Lqh III, which has been reported to slow inactivation of Na v 1.7 (Chen et al., 2002) alone and in combination with 1 μM PF-06526290, is shown in Figure 7C . Application of 300 nM Lqh III slowed Na v 1.7 channel inactivation (τ inact = 10 ± 1 ms compared to τ inact = 0.8 ± 0.1 ms for control). However, the slowing was approximately 10-fold less than observed with 1 μM PF-06526290 (τ inact = 96 ± 9 ms). If PF-06526290 and Lqh III interacted at the same or overlapping binding site, we would expect competition and thus the rate inactivation in the presence of both agents would be predicted to faster than PF-06526290 alone and slower than Lqh III alone. However, when both 300 nM Lqh III and 1 μM PF-06526290 were applied in combination, Na v 1.7 inactivation was further slowed to τ inact = 1100 ± 64 ms ( Figure 7C, D) . The synergistic actions of co-administered Lqh III and PF-06526290 suggest independent but functionally coupled interactions with the channel.
It is known that other enhancers ("activators") of Na v channel conduction like batrachotoxin, veratridine and pyrethroids interact with the region near or overlapping with the canonical local anaesthetic binding site on the D4 S6 transmembrane segment of the pore (Ragsdale et al., 1994; Ragsdale et al., 1996; Son et al., 2004) . Therefore, we
Figure 6
Properties of PF-06526290 induced slowing of Na v channel inactivation. (A) Current traces of Na v 1.7 channels in the absence and presence of 0.1, 1 and 10 μM PF-06526290. Sodium currents were elicited by voltage steps to 0 mV for 500 ms from a holding potential of À120 mV (current amplitudes are normalized to peak for each trace). (B) Same sodium current traces from (A) normalized to peak and plotted on a log scale. (C) Time constant of inactivation (τ) in the absence and presence of 0.1, 1 and 10 μM PF-06526290 (n = 4-7 cells from four cell preparations). Current decay was fit with a single exponential. There was no significant difference between the calculated time constants for slow phase of inactivation at different concentrations of PF-06526290. *P < 0.05, significantly different from control; One way ANOVA with Tukey's post hoc test (D) Na v 1.7 current trace evoked by a single pulse depolarization to 0 mV for 20 ms from a holding potential of À120 mV the in presence of 1 μM PF-06526290. (E) Current traces elicited by the voltage protocol shown in the presence of 1 μM PF-06526290. A 500 ms depolarizing voltage step to 0 mV was applied to functionally displace PF-06526290. A rest period at À120 mV of variable duration was applied prior to a 20 ms test pulse (indicated by #) to assess fraction of current exhibiting slowed inactivation. (F) Concentration dependence of time course for recovery of slowed inactivation after 500 ms voltage step to 0 mV in the presence of PF-06526290. The I 5ms /I peak current amplitude ratios determined during the test pulse (#) are plotted against time at À120 mV after 500 ms voltage step to 0 mV. τ Recovery was determined from a least squares fit of a double exponential with the slow phase contributing 92-94% of the recovery for each concentration and τ slow being 2311 ± 18 ms (n = 6), 994 ± 121 ms (n = 6) 540 ± 72 ms (n = 6) and 363 ± 63 ms (n = 5) for 0.3, 1, 3 and 10 μM PF-06526290 respectively. For comparison, the time course for recovery of Na v 1.7 inactivation following a 500 ms voltage step to 0 mV in the absence of PF-06526290 is also shown (Control). Data were fit with a double exponential with τ fast = 11 ± 2, τ slow = 270 ± 128 ms and fast/slow ratio of 0.74. Results shown in (D-F) were obtained using Molecular Devices PatchXpress automated patch clamp platform.
Multiple modes of Na v channel modulation by PF-06526290 examined the effect of 10 μM PF-06526290 on a Na v 1.7 F1737A/Y1744A mutant, which we have previously shown to decrease local anaesthetic potency by >100-fold (McCormack et al., 2013) . Figure 7E , F shows that no reduction in PF-06526290-induced slowing of inactivation was observed with Na v 1.7 F1737A/Y1744A suggesting that this Figure 7 (A) Introduction of M123 (S1510Y/R1511W/E1559D) residues into Na v 1.7 increases sensitivity to inhibition by PF-06526290 whereas introduction of M123 (Y1537S/W1538R/D1586E) residues into Na v 1.3 reduces its sensitivity to inhibition by PF-06526209 [IC 50 : 5 ± 2 μM (n = 6 cells) for Na v 1.3, 30 ± 5 μM (n = 3 cells) for Na v 1.3 M123, >100 μM (n = 6 cells) for Na v 1.7 and 35 ± 4 μM (n = 3 cells) for Na v 1.7 M123] (from at least two separate cell preparations). (B) Mutation of M123 residues has no effect on PF-06526290-induced slowing of inactivation in either Na v 1.3 or Na v 1.7 [EC 50 : 1.1 ± 0.1 μM (n = 5 cells) for Na v 1.3, 1.1 ± 0.4 μM (n = 4 cells) for Na v 1.3 M123, 0.27 ± 0.08 μM (n = 6 cells) for Na v 1.7, and 0.39 ± 0.13 μM (n = 3 cells) for Na v 1.7 M123] (from at least two separate cell preparations). (C) Na v 1.7 current traces recorded in the presence of 300 nM scorpion toxin Lqh III, 1 μM PF-06526290 (PF-290) or mixture of 300 nM Lqh III + 1 μM PF-06526290. Currents were elicited by a 5 s voltage step from À120 to 0 mV (traces show the first 500 ms). (D) Plot of inactivation time constants (τ inact ) in the absence and presence of 300 nM Lqh III (n = 6), 1 μM PF-06526290 (PF-290) (n = 5) or a mixture of 300 nM Lqh III + 1 μM PF-06526290 (n = 9). τ inact was determined from a fit of a single exponential equation. Data derived from three separate cell preparations. *P < 0.05, significantly different from control; One way ANOVA with Tukey's post hoc test. (E) Current traces comparing effect of 10 μM PF-06526290 on inactivation of Na v 1.7 versus the local anaesthetic binding site mutant Na v 1.7 F1737A/Y1744A. (F) Plot of I 5ms /I peak current amplitude ratio for both Na v 1.7 and Na v 1.7 F1737A/ Y1744A in the presence and absence of 10 μM PF-06526290 Data shown are from six to nine separate experiments. *P < 0.05, significantly different as indicated; N.S., not significant; One way ANOVA with Tukey's post hoc test.
Figure 8
PF-06526290 slows inactivation of endogenous Na v currents and increases neuronal excitability in mouse sensory neurons. (A) Sodium current traces showing the slowing of inactivation by 10 μM PF-06526290 in the absence or presence of 200 nM TTX to isolate the TTX-resistant component. Sodium currents were elicited by a single pulse test to 0 mV for 20 ms from a holding potential of À120 mV. (B) Plot of the I 5ms /I peak current amplitude ratio for TTX-sensitive and -resistant currents in the presence of 10 μM PF-06526290 (n = 8-10 neurons recorded over 3 days from two separate cell isolations). *P < 0.05, significantly different as indicated; N.S., not significant; One way ANOVA with Tukey's post hoc test. (C) Effect of 0.3 μM PF-06526290 on stimulus intensity (current injection in pA) required to initiate action potential. (D) Plot of current injection threshold for initiation of action potential in the presence and absence of 0.3 μM PF-06526290 (n = 6 neurons recorded over 3 days from two separate cell isolations). *P < 0.05, significantly different as indicated; N.S., not significant; Student's t-test. (E) Time-dependent change in number of action potentials elicited by a 500 ms 150 pA supramaximal stimulus at 0.1 Hz in the absence or following administration of 0.3 μM PF-06526290. Plot time course of action potential frequency (F) or duration at 50% repolarization (G), in the absence or following administration 0.3 μM PF-06526290 using stimulus protocol used in (E) (n = 6 neurons recorded over 2 days from two separate cell isolations).
region of the channel is probably not involved in PF-06526290's conduction enhancing actions.
PF-06526290 slows inactivation of native Na v currents and increases excitability in sensory neurons
Slowing of Na v channel inactivation by scorpion and anemone toxins are associated with increased neuronal excitability (Benoit and Gordon, 2001; Yamaji et al., 2009) . To determine if the PF-06526290 produces a similar effect, we examined its actions on mouse DRG sodium currents and action potential properties. PF-06526290 slowed inactivation of both TTXsensitive and -resistant sodium currents in mouse DRG neurons ( Figure 8A, B) . PF-06526290 at 10 μM was applied in the absence and presence of 200 nM TTX used to isolate TTX-resistant component. In the absence of TTX, 10 μM PF-06526290 slowed inactivation such that current amplitude 5 ms after start of depolarizing voltage step was 76 ± 3% of peak versus 8 ± 1% for control currents ( Figure 8B ). In the presence of 200 nM TTX, slowing of inactivation was less profound (I 5ms /I peak = 42 ± 5% vs. 17 ± 3% for control) but was similar in profile and magnitude to that seen with recombinant Na v 1.8 currents ( Figure 3E) . Figure 8C -G shows the effect of PF-06526290 on mouse DRG neuron excitability. In the presence of 0.3 μM PF-06526290, the action potential threshold was reduced ( Figure 8C, D) . Using a supramaximal 500 ms stimulation of 150 pA to evoke action potential firing, 0.3 μM PF-06526290 initially increased the frequency of action potential firing, which progressed to prolongation of action potential duration with APD 50 > 400 ms after 3 min of exposure ( Figure 8E-G) .
To test the possibility that prolongation of action potential duration by PF-06526290 may be due in part to inhibition of potassium channels, we examined the effect of the agent on the neuronal delayed rectifier K v 1.1/1.2 channels. No inhibition by PF-06526290 was observed up to 10 μM (Supporting Information Figure S1 ).
Discussion
The present study has focused on expanding our understanding of modulation of Na v channels by a new agent that exhibits both inhibition and enhancement of current flow. PF-06526290 greatly slows inactivation, which occurs with all Na v channel subtypes examined. PF-06526290 also slows inactivation of TTX-sensitive and -resistant Na v currents in mouse sensory neurons, which is associated with action potential prolongation and increased frequency of firing similar to that observed with scorpion and anemone toxins, which also slow Na v channel inactivation (Benoit and Gordon, 2001; Abbas et al., 2013) .
In contrast to its ability to slow inactivation, which appears to result from an interaction with closed channels, PF-06526290 was found to selectively inhibit Na v 1.3 rather than Na v 1.7 channels via an apparent preferential interaction with inactivated state(s) of the channel. Similarly, the switching of Na v 1.3 to Na v 1.7 selectivity via the mutation of the M123 motif suggests that inhibition might be mediated via an interaction with the homologous domain 4 voltage sensor. The magnitude of the M123 motif mutation-induced modulation of the inhibitory effects of PF-06526290 is less than reported for aryl sulfonamide inhibitors like PF-04856264 and PF-05089771 (McCormack et al., 2013; Alexandrou et al., 2016) . However, this may reflect the involvement of other residues for interaction, especially given the structural differences between these classes of molecule. The involvement of other residues beyond M123 motif for aryl sulfonamide Na v 1.7 channel inhibitors has also been described (McCormack et al., 2013; Ahuja et al., 2015) . Alternatively, the shifts in potency observed with the Na v 1.7 M123 mutation may reflect an indirect effect of modulating the voltage-gating process which is translated to other regions of the channels that may be the site of PF-06526290 interaction.
The Na v channel subtype-independent slowing of inactivation observed with PF-06526290 appears to result from an interaction with resting closed state(s) (and possibly open states). Although inactivation of Na v channels is slowed in the presence of PF-06526290, prolonged depolarization (>500 ms) eventually results in inactivation reaching completion, and the rate at which this is achieved is independent of concentration applied. This finding can be interpreted as PF-06526290 interaction leads to inhibition of fast inactivation to expose a slower inactivation process that is not affected by it. Our observation that PF-06526290 does not produce a concentration-dependent shift in the voltage dependence of inactivation but rather increases the proportion of channels that inactivate with a more depolarized midpoint potential (À32 vs. À70 mV for unmodified channels) is consistent with this hypothesis. We also found that the establishment of slowed inactivation results in the functional displacement of PF-06526290 from the channel despite its continued presence and re-interaction only occurs after the channels return to the resting closed state.
While the functional displacement of PF-06526290 was most evident with Na v 1.7 channels (due to the absence of an inhibitory effect), it was also observed with the noninhibited component of Na v 1.3 channels, suggesting that resting state-dependent slowing of inactivation and inactivated state-dependent inhibition are functionally distinct processes. Finally, while the inhibitory actions of PF-06526290 is modulated by M123 motif mutation of domain 4 VSD, these mutations had no effect on slowing of inactivation of either Na v 1.3 or Na v 1.7 channels. It can be noted that the absence of effect of M123 motif mutation on PF-06526290-induced slowing of inactivation does not exclude the possibility that this effect is still mediated via an interaction with the domain 4 VSD, as the mutations swapped Na v 1.3 for Na v 1.7 residues or vice versa, and both channel subtypes exhibit a slowed inactivation in the presence of this modulator.
Homologous domain 4 VSD has been shown to be the site of interaction for scorpion and anemone peptide toxins, which, like PF-06526290, cause slowing of inactivation of Na v channels (Rogers et al., 1996; Leipold et al., 2004; Billen et al., 2008; Wang et al., 2011; Gilchrist et al., 2014; MartinEauclaire et al., 2015) . Interestingly, site 3 scorpion α and anemone toxins achieve their modulation of inactivation via an interaction with amino acid residues that include the third residue of the M123 motif (E1559 on Na v 1.3 and D1586 on Na v 1.7) (Rogers et al., 1996; Leipold et al., 2004; Wang et al., 2011; Gurevitz, 2012; Gilchrist et al., 2014) . Given the similar mode of channel modulation and preference for resting state channels, as well as the overlap of D4 VSD regions important for toxin action and the inhibitory effects of PF-06526290, we explored possible interaction of the α-like toxin Lqh3 with PF-06526290. If the two agents interact with a common site, we would expect that the time course of slowing of inactivation when the Lqh3 and PF-06526290 are applied together would be somewhere between the time courses observed with each agent applied individually. In contrast to this expectation, inactivation was slowed a further 10-fold, suggesting synergism between Lqh3 and PF-06526290. This implies that Lqh3 and PF-06526290 have functionally coupled but distinct interactions with the channel. However, as with the M123 mutations, these findings do not exclude the possibility that the slowed inactivation still results from an interaction with the D4 VSD.
We did explore the possibility that PF-06526290 might interact with the local anaesthetic binding site within the pore since a number of Na v channel activators like veratridine are reported to interact with or near this region of the channel (Son et al., 2004; Tikhonov and Zhorov, 2005; YoshinakaNiitsu et al., 2012) . However, we found that mutation of the local anaesthetic binding site on Na v 1.7 site did not prevent PF-06526290-mediated slowing of inactivation, suggesting that this region is probably not involved in the interaction producing this effect.
Currently, the region of the sodium channel responsible for PF-06526290-induced slowing of inactivation remains elusive. We have not been able to exclude the possibility that the effect is mediated via an interaction with the domain 4 VSD, so future studies directed towards investigating the potential role of other residues in the region may help in this regard. Of course, there remains the possibility that the site of interaction mediating the slowed inactivation is located elsewhere, including other VSDs. We have shown that the magnitude of slowing of inactivation of Na v 1.4 and Na v 1.8 channels is considerably less than that observed with the other Na v channel subtypes. It may be possible to exploit these differences in future studies to construct homologous domain swap chimeras to home in on potential regions of interaction in a manner similar to that successfully employed to identify the D4 VSD interaction site for selective inhibitors (McCormack et al., 2013) . Potential guidance can also come from examining previously characterized agents which have both enhancing and inhibitory effects. For example, the dual inhibition and slowing of voltage-dependent sodium channel inactivation has also been reported for the cardiac inotropic agent DPI 201-106 (Romey et al., 1987; Wang et al., 1990) . The (S)-enantiomer of DPI 201-106 slows inactivation whereas the (R)-enantiomer inhibits Na v channel function. The exact location on the channel mediating these effects remains to be reported, although a detailed study by Wang et al. (1990) did provide evidence that slowing of inactivation and inhibition was mediated by separate non-overlapping interactions with the channel. The enantiomer-dependent effects of DPI 201-106 are reminiscent of the voltage-dependent calcium channel inhibition/activation elicited by enantiomers of dihydropyridines (Hockerman et al., 1997; Natale and Steiger, 2014) which have been reported to result from interactions with the homologous domains 3 and 4 S5 and S6 transmembrane helices that form the pore (Peterson et al., 1996; Hockerman et al., 1997; Schleifer, 1999) . Similar inhibition/activation switching has been reported for modulators of TRPA1 and potassium channels as well as agonist/inverse agonists of GABA receptor channels (Ferretti et al., 2004; Defalco et al., 2010; Banzawa et al., 2014) .
In conclusion, the findings from the current study have shown that a single agent, PF-06526290, can exhibit both enhancement and inhibition of sodium channel function. This dual mode of Na v channel modulation likely results from distinct interactions with the channel. The ability of PF-06526290 to interact with distinct gating states to elicit opposing effects on conduction may make it a useful tool for further understanding how pharmacological modulation of gating leads to conduction changes.
Although much of the historical focus on developing drug candidates targeting voltage-dependent sodium channels has been directed towards inhibitors, there has recently been increased interest in developing agents that can enhance sodium channel function/conduction. Seizure and autism spectrum disorders associated with human loss of function mutations of Na v 1.1, Na v 1.2, Na v 1.3 and Na v 1.6 channels may benefit from pharmacological enhancement of channel conduction. Therefore, improved understanding of the site of action of agents like PF-06526290 may provide opportunities to develop more subtype-selective enhancers of Na v channels, which in turn could provide new treatment options for rare epilepsies and other neurological disorders like autism.
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